Study of Metastatic Ocular Melanoma

Charite University, Berlin, Germany48 enrolled

Overview

This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma.

Treatment of patients with metastatic ocular melanoma with combination chemotherapy Gemcitabine and Treosulfan versus monotherapy with Treosulfan as first-line chemotherapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Ocular Melanoma

Interventions

GemcitabineDRUG

TreosulfanDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Metastatic ocular melanoma Exclusion Criteria: * Prior treatment with chemotherapy * Active 2nd malignancy * Cerebral metastasis

Locations (1)

Hematology & Oncology Charité CBF Berlin

Berlin, State of Berlin, Germany

RECRUITING

Outcomes

Primary Outcomes

Determination of efficacy according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria

Secondary Outcomes

Time to progression

Central Contacts

Ulrich Keilholz, MD

CONTACT

+49-30-8445-3596 ulrich.keilholz@charite.de

Alexander Schmittel, MD

CONTACT

+49-30-8445-3090 alexander.schmittel@charite.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.